Shares of Rallybio Corp. (RLYB) are up 71% on Thursday following the announcement of a partnership with Johnson & Johnson (JNJ) aimed at advancing therapeutic approaches to mitigate the risk of fetal and neonatal alloimmune thrombocytopenia also known as FNAIT.
RLYB is trading on the Nasdaq at $2.79, up 71.47% or $1.16 per share. It has traded between $1.22 and $9.14 in the past 52-week period.
Additionally, Rallybio secured a $6.6 million equity investment from Johnson & Johnson Innovation.
The company is working on RLYB212, a human monoclonal anti-HPA-1a antibody designed to prevent FNAIT by halting the production of alloantibodies in expecting mothers.
Rallybio intends to commence a Phase 2 trial for RLYB212 in the latter part of 2024.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.